Loading the security overview…
Where the tokens are
| Quarter | Reported | EPS | EPS vs year ago | Revenue | Revenue vs year ago | Consensus EPS |
|---|---|---|---|---|---|---|
| Q3 FY26ended Jun 30, 2026 | Aug 6, 2026 | −$1.36 | — | $75.25M | +171.0% | −$1.19 |
| Q2 FY26ended Mar 31, 2026 | May 11, 2026 | −$0.93 | −133.8% | $73.74M | −86.4% | −$1.04 |
| Q1 FY26ended Dec 31, 2025 | — | $0.22 | — | $264.03M | +10461.3% | — |
| Q4 FY25ended Sep 30, 2025 | — | −$0.18 | — | $256.47M | — | — |
| Q3 FY25ended Jun 30, 2025 | — | −$1.26 | — | $27.77M | — | — |
| Q2 FY25ended Mar 31, 2025 | — | $2.75 | — | $542.71M | — | — |
| Q1 FY25ended Dec 31, 2024 | — | −$1.39 | — | $2.50M | −29.6% | — |
| Q4 FY24ended Sep 30, 2024 | — | −$1.37 | — | $0 | −100.0% | — |
| Q3 FY24 |
Growth compares each quarter with the same fiscal quarter a year earlier, and is left blank where that quarter is missing or its figure was zero or a loss. Consensus is the estimate published before each report. It usually refers to adjusted EPS, so it is shown beside the GAAP figure rather than subtracted from it: the difference would not be a beat or a miss.
Figures describe Arrowhead Pharmaceuticals shares, not any token. As of Aug 6, 2026, from Massive's standardised financials and the earnings calendar.
| — |
| −$1.38 |
| — |
| — |
| — |
| — |
| Q2 FY24ended Mar 31, 2024 | — | −$1.02 | — | — | — | — |
| Q1 FY24ended Dec 31, 2023 | — | −$1.24 | — | $3.55M | — | — |
| Q4 FY23ended Sep 30, 2023 | — | −$1.02 | — | $16.10M | — | — |